Microsampling with Impact-Assisted Extraction for Hematocrit-Free Assays
Volumetric Microsampling with Hybridization LC–MS/MS for Antisense Oligonucleotide Quantitation
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development
Laval, QC, Canada, July 31, 2025 — Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a strategic collaboration aimed at enhancing preclinical research and accelerating the path from discovery to clinical trials.
This partnership combines Altasciences’ comprehensive early-phase drug development capabilities with VoxCell’s cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment. By integrating VoxCell’s high-resolution 3D bioprinted tissue platforms into Altasciences’ discovery and preclinical services, both companies aim to reduce R&D timelines and increase the success rate of investigational therapies.
“We’re proud to partner with VoxCell BioInnovation to bring next-generation tissue modeling into the early stages of drug development,” said Steve Mason, Co-Chief Operating Officer at Altasciences. “This collaboration aligns with our commitment to the 3Rs as well as to innovative, efficient solutions that improve data quality and accelerate decisions for our clients.”
VoxCell’s proprietary bioprinted tissues are engineered to closely mimic the complexity of human tumors and other biological structures, offering drug developers an advanced platform for evaluating efficacy, safety, and toxicity—before moving into animal or human studies.
“Our mission has always been to make drug screening more human-relevant and predictive,” said Karolina Valente, CEO of VoxCell BioInnovation. “Altasciences shares this forward-thinking approach, and we’re excited to work together to support pharmaceutical and biotech companies in making faster, more informed decisions.”
The collaboration will focus initially on drug screening for ocular indications, with plans to expand into additional therapeutic areas and applications.
This partnership represents a shared vision: to transform early stage research through innovation, integration, and smarter science—delivering better outcomes for patients worldwide.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, research support, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.
Julie-Ann Cabana
Altasciences
jcabana@altasciences.com
Highlights From the International Society for the Advancement of Cytometry Conference 2025 by Martin Turcotte
CYTO 2025, the 38th annual Congress of the International Society for the Advancement of Cytometry, is the premier, inclusive, and international conference on the many facets of cytometry science and engineering.
ISSUE NO. 45 — Discovery Studies: An Agile Approach to Early Data for Quicker Decisions
The early identification of toxicity, and flexibility to explore parameters and characteristics of drug candidates in vivo via early discovery non-GLP studies, allow for improved drug development strategy and faster go/no-go decisions. This data from animal models, and particularly nonhuman primates (NHPs) where their genetic, immunologic, and physiologic similarities to humans make them the model of choice, is an important part of informing decisions about candidate molecules.
Access to early discovery studies’ data accelerates the process of refining candidate molecules and identifying promising therapeutic targets, novel delivery methods, and pharmacodynamic markers.
In Issue 45 of The Altascientist, we explore:
- the characteristics and advantages of non-GLP discovery studies
- emerging trends in drug delivery methods two early-stage biodistribution case studies
Highlights From the 2025 American Society for Mass Spectrometry Conference | By Jean-François Larocque and Benjamin Charron
We were thrilled to represent Altasciences at this year’s American Society for Mass Spectrometry (ASMS) conference in Baltimore. With 6,000 scientists, students, and industry professionals from around the globe in attendance, it was an excellent opportunity to learn about the latest developments in mass spectrometry and share insights with other passionate scientists.
Altasciences at ASGCT 2025: An Open Forum for All Things Gene and Cell Therapy | By Kaylyn Koenig
I recently returned from attending the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. This was my first conference since joining Altasciences, and I was excited to attend with some of my esteemed colleagues, Nobert Makori (Vice President of Toxicology), Steve Mason (Co-COO), and members of the Business Development team, Derek Storey, Gretchen Green, Todd Hartz, and Mike Zamora.
ISSUE 44 — The Importance of Cytokine Release Assays to Derisk the Development of Immunomodulatory Drugs
New immunomodulatory drugs have the potential to cause serious immune-related adverse events, including cytokine release syndrome (CRS). CRS is a systemic inflammatory response characterized by the release of
In Issue 44 of The Altascientist, we review strategies, including those implemented at Altasciences, for developing, qualifying, and implementing cytokine release assays (CRAs) to assess the safety of test articles in vitro to complement in vivo preclinical safety assessments, in addition to:
- the importance of nonclinical cytokine release evaluation
- customized approaches to CRA use in drug development
- top five aspects to consider before running a CRA
- Altasciences’ case results
- how Altasciences can help
Drugs that are likely to require CRAs as part of derisking their development include, but are not limited to: